Cargando…
Steroid Minimization in Adults with Minimal Change Disease
BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recogn...
Autores principales: | Koirala, Abbal, Jefferson, J. Ashley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677715/ https://www.ncbi.nlm.nih.gov/pubmed/36751385 http://dx.doi.org/10.1159/000517626 |
Ejemplares similares
-
Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis
por: Aslam, Ahsan, et al.
Publicado: (2023) -
Minimal-change disease secondary to etanercept
por: Koya, Mariko, et al.
Publicado: (2012) -
Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
por: Kannan, Lakshmi
Publicado: (2022) -
Abatacept in Steroid-Dependent Minimal Change Disease and CD80-uria
por: Isom, Robert, et al.
Publicado: (2019) -
Nephron Number and Time to Remission in Steroid-Sensitive Minimal Change Disease
por: Sasaki, Takaya, et al.
Publicado: (2020)